抗生素序贯疗法在儿童支气管肺炎中的应用

Application of sequential antibiotic therapy in children with bronchopneumonia

目的观察临床应用阿奇霉素序贯治疗儿童急性支气管肺炎的价值。方法选取2016年2月至2017年1月因急性支气管肺炎住院患儿67例,将入选患儿随机分为对照组与序贯疗法组,对照组按常规静脉应用乳糖酸阿奇霉素注射液5~10 mg/(kg·d),连续应用1周,序贯疗法组应用乳糖酸阿奇霉素注射液5~10 mg/(kg·d),治疗3~5 d后,如血白细胞在正常范围且体温连续24 h正常,即认为病情稳定后改用阿奇霉素颗粒口服,疗程5~7 d。入选患儿均常规应用抗病毒药物,化痰,合并有低氧血症、呼吸困难者予维持呼吸道通畅,氧疗及对症支持治疗。结果对照组32例中25例痊愈,痊愈率78.12%;显效5例,显效率15.62%;2例无效,无效率6.25%;总有效率93.75%。序贯疗法组35例中29例痊愈,痊愈率82.85%;显效4例,显效率11.42%;2例无效,无效率5.71%;总有效率94.28%。2组总有效率差异有统计学意义(P>0.05)。结论临床应用阿奇霉素序贯治疗儿童急性支气管肺炎疗效确切,治疗费用低廉,副作用少且依从性高,是治疗儿童急性支气管炎的一种较为理想的方法,临床上值得推广应用。

Objective To evaluate the effectiveness of sequential azithromycin therapy for children with bronchopneumonia. Methods A total of 67 cases of children with bronchopneumonia were randomized divided into a SAT group（by sequential therapy） and a control group（by persistent intravenous drop infusion with azithromycin）. The recovery rates and overall efficacy rates of the two groups were evaluated and compared. Results The recovery rates of the SAT group and control group were 94.28%（33/35） and 93.75%（30/32） respectively（P〉0.05）, there was no significant difference in the clinical effect between the SAT group and control group. No adverse effects were found in the two groups. Conclusion The sequential therapy of azithromycin for children with bronchopneumonia is safe and valid.